Novel Delivery Systems and Pharmacotherapeutic Approaches for the Treatment of Non–muscle-invasive Bladder Cancer
-
Published:2024-06
Issue:
Volume:
Page:
-
ISSN:2588-9311
-
Container-title:European Urology Oncology
-
language:en
-
Short-container-title:European Urology Oncology
Author:
Guerrero-Ramos FélixORCID,
Boormans Joost L.,
Daneshmand Siamak,
Gontero Paolo,
Kamat Ashish M.,
Rouprêt Morgan,
Vilaseca Antoni,
Shariat Shahrokh F.
Reference55 articles.
1. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study;Balar;Lancet Oncol,2017
2. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma;Powles;N Engl J Med,2020
3. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer;Powles;N Engl J Med,2024
4. BCG unresponsive non-muscle invasive bladder cancer: the beginning of a new era?;Guerrero-Ramos;Actas Urol Esp,2023
5. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study;Balar;Lancet Oncol,2021